相关实验视频
Updated: May 12, 2026
11:53
Cecal Ligation Puncture Procedure
Published on: May 7, 2011
54.7K
Clostridium butyricum,在败血症治疗中的未来明星
Jinglin Zhao1, Li Jiang1, Weizhi He1
1Medical Laboratory, Kunming Children's Hospital, Children's Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.
Frontiers in cellular and infection microbiology
|December 23, 2024
概括
(C. butyricum) 通过调节肠道微生物群,在治疗败血症方面表现有前途. 对C.butyricum进行进一步的研究.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 败血症是一种危及生命的器官功能障碍,是由宿主对感染反应失调引起的.
- 肠道微生态和肠道微生物群越来越多地被认为是败血症发展和进展的关键因素.
- 肠道失生症与败血症的发病有关,影响免疫功能和肠道屏障完整性.
研究的目的:
- 审查Clostridium butyricum (C.butyricum) 在人类疾病,特别是肠道疾病中作为益生菌的作用.
- 评估目前关于C.butyricum在败血症治疗中的治疗潜力的研究.
- 根据C. butyricum的机制,确定毒症的潜在治疗点.
主要方法:
- 文献综述侧重于调查C. butyricum和败血症的研究.
- 对C.butyricum对肠道微生物群,免疫功能和肠道屏障的影响的研究分析.
- 关于C.butyricum在败血症模型和临床背景中的作用的综合证据.
主要成果:
- 在各种肠道疾病和感染中,C.butyricum已经显示出保护作用.
- 新出现的证据表明,C.butyricum可以调节肠道微生物群的组成和功能.
- 研究表明,C.butyricum可以减轻炎症反应,并改善与败血症相关的肠道屏障完整性.
结论:
- C.butyricum作为治疗败血症的益生菌干预措施具有显著的潜力.
- 通过C.butyricum调节肠道微生物群是其保护作用的关键机制.
- 对C.butyricum的治疗应用进行进一步的研究可能会导致新的败血症治疗方法.
相关概念视频
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:27Production of Antibiotics
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
01:29Staphylococcal Skin Infections
Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:22Bacterial Meningitis I: Introduction
Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
01:26Bacterial Meningitis II: Pathophysiology
Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...